Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.77 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.77 |
| ▸ | PNMT | P11086 | 6/20 | 0.54 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.54 |
| ▸ | CD44 | P16070 | 1/20 | 0.54 |
| ▸ | MAOB | P27338 | 1/20 | 0.54 |
| ▸ | ASIC3 | Q9UHC3 | 3/20 | 0.46 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.45 |
| ▸ | DRD2 | P14416 | 2/20 | 0.43 |
| ▸ | DRD3 | P35462 | 2/20 | 0.43 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.41 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.41 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30183351 | 1.00 | CHRNB2 (0.77) | CHRNB2CHRNA4PNMTSIGMAR1CD44 | |
| Hydrochloric Acid SCHEMBL29759853 | 0.98 | CHRNB2 (0.74) | CHRNB2CHRNA4PNMTSIGMAR1CD44 | |
| Hydrochloric Acid SCHEMBL785959 | 0.98 | CHRNB2 (0.74) | CHRNB2CHRNA4PNMTSIGMAR1CD44 | |
| SCHEMBL29850369 | 0.92 | CHRNB2 (0.77) | CHRNB2CHRNA4PNMTSIGMAR1CD44 | |
| SCHEMBL587887 | 0.92 | CHRNB2 (0.77) | CHRNB2CHRNA4PNMTSIGMAR1CD44 | |
| Hydrochloric Acid SCHEMBL15238605 | 0.90 | CHRNB2 (0.74) | CHRNB2CHRNA4PNMTSIGMAR1CD44 | |
| Hydrochloric Acid SCHEMBL4790441 | 0.90 | CHRNB2 (0.74) | CHRNB2CHRNA4PNMTSIGMAR1CD44 | |
| SCHEMBL19194503 | 0.88 | SIGMAR1 (0.61) | CHRNB2CHRNA4PNMTSIGMAR1CD44 | |
| SCHEMBL19200207 | 0.87 | CHRNB2 (1.00) | CHRNB2CHRNA4PNMTSIGMAR1CD44 | |
| SCHEMBL1118591 | 0.82 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 524 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111655695-B | Substituted furopyrimidine compounds as PDE1 inhibitors | 达特神经科学有限公司 | 2025-05-27 | — | — | CN | claimed |
| EP-3717488-A1 | SUBSTITUTED FURANOPYRIMIDINE COMPOUNDS AS PDE1 INHIBITORS | Dart NeuroScience, LLC (US) | 2020-10-07 | — | — | EP | claimed |
| CN-111655695-A | Substituted furopyrimidines as PDE1 inhibitors | 达特神经科学有限公司 | 2020-09-11 | — | — | CN | claimed |
| EP-3129371-B1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | SYROS PHARMACEUTICALS INC (US) | 2020-07-29 | — | — | EP | claimed |
| WO-2019104285-A1 | SUBSTITUTED FURANOPYRIMIDINE COMPOUNDS AS PDE1 INHIBITORS | DART NEUROSCIENCE, LLC (US) | 2019-05-31 | — | — | WO | claimed |
| US-20100130495-A1 | COMPOUNDS 563 | ASTRAZENECA AB (SE) | 2010-05-27 | — | — | US | claimed |
| EP-1899334-A2 | NAPHTHYRIDINE COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-03-19 | — | — | EP | claimed |
| WO-2006138714-A2 | NAPHTHYRIDINE COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-12-28 | — | — | WO | claimed |
| US-12629358-B2 | Compound used as RET kinase inhibitor and application thereof | TYK MEDICINES, INC. (CN) | 2026-05-19 | — | — | US | disclosed |
| US-12624043-B2 | Compositions useful for treating disorders related to kit | BLUEPRINT MEDICINES CORPORATION (US) | 2026-05-12 | — | — | US | disclosed |
| EP-4155304-B9 | COMPOUND USED AS RET KINASE INHIBITOR AND APPLICATION THEREOF | TYK MEDICINES INC (CN) | 2026-04-15 | — | — | EP | disclosed |
| US-12595265-B2 | Inhibitors of activin receptor-like kinase | BLUEPRINT MEDICINES CORPORATION (US) | 2026-04-07 | — | — | US | disclosed |
| EP-4714948-A1 | COMPOUND USED FOR EGFR PROTEIN DEGRADATION, AND USE THEREOF | TYK Medicines, Inc. (CN) | 2026-03-25 | — | — | EP | disclosed |
| US-12583856-B2 | Inhibitors of protein kinase A | BLUEPRINT MEDICINES CORPORATION (US) | 2026-03-24 | — | — | US | disclosed |
| WO-2001044250-A1 | SUBSTITUTED 1,2,3-TRIAZOLO[1,5-a]QUINAZOLINES FOR ENHANCING COGNITION | MERCK SHARP & DOHME LIMITED (GB) | 2001-06-21 | — | — | WO | disclosed |
| EP-0321191-B1 | Heterocyclic-substituted quinoline-carboxylic acids | PFIZER (US) | 1994-11-02 | — | — | EP | disclosed |
| US-5214051-A | Thiazolyl and oxazolyl[5,4-c]piperidyl-substituted quinolone-carboxylic acid and related analogs thereof having antibacterial properties are disclosed | PFIZER INC. (US) | 1993-05-25 | — | — | US | disclosed |
| US-5037834-A | Heterocycylic-substituted quinoline-carboxylic acids | PFIZER INC. (US) | 1991-08-06 | — | — | US | disclosed |
| WO-1989005643-A1 | HETEROCYCLIC-SUBSTITUTED QUINOLINE-CARBOXYLIC ACIDS | PFIZER INC. (US) | 1989-06-29 | — | — | WO | disclosed |
| EP-0321191-A2 | Heterocyclic-substituted quinoline-carboxylic acids | PFIZER INC. (US) | 1989-06-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12624043-B2 | Compositions useful for treating disorders related to kit | KIT, RET, SLC26A4 | CHRNB2 1417/4885CHRNA4 1339/4885PNMT 1096/4885 |
| US-12583856-B2 | Inhibitors of protein kinase A | CSNK1A1, CSNK1A1L, CSNK1G1 | CHRNB2 1646/4885CHRNA4 1385/4885PNMT 4642/4885 |
| US-20100130495-A1 | COMPOUNDS 563 | BACE1, PSEN1, PSEN2 | CHRNB2 43/4885CHRNA4 85/4885PNMT 270/4885 |
| US-12595265-B2 | Inhibitors of activin receptor-like kinase | ACVR1, ACVRL1, ACVR2A | CHRNB2 89/4885CHRNA4 403/4885PNMT 4593/4885 |
| US-12629358-B2 | Compound used as RET kinase inhibitor and application thereof | RET, ALK, FGFR3 | CHRNB2 1839/4885CHRNA4 2237/4885PNMT 4558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.